Almirall initiates phase 3 study of drug targeting autoimmune dermatological diseases

Almirall has announced the initiation of a phase 1 study evaluating ALM27134 for the treatment of autoimmune dermatological diseases, according to a company press release.

“The start of the first clinical study of ALM27134 encourages us to continue working on the testing and development of this high-potential first-in-class treatment,” Karl Ziegelbauer, PhD, chief scientific officer of Almirall, said in the release. “We have the ambition to continue sharing further milestones in the future of this monoclonal antibody.”

ALM27134, a first-in-class fully human, high-affinity monoclonal antibody, targets interleukin-1 receptor accessory protein (IL-1RAP) to treat autoimmune dermatological diseases. IL-1RAP abrogates multiple disease drivers among the IL-1 family of proinflammatory cytokine receptors. These cytokine receptors — including IL-1R, IL-33R and IL-36R — have been implicated in many dermatological autoimmune diseases.

The first dose of ALM27134 has been administered to a healthy volunteer. The trial will continue to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of the drug.